2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Adult Pure Erythroid Leukemia
National Cancer Institute (NCI)Small moleculePhase 3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Adult Pure Erythroid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Azacitidine National Cancer Institute (NCI) | Phase 2 | B |
METHOTREXATE National Cancer Institute (NCI) | Phase 2 | B |
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 2 | B |
Romidepsin National Cancer Institute (NCI) | Phase 2 | B |
Cediranib National Cancer Institute (NCI) | Phase 2 | B |
View all 24 →
Same molecule, other indications
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →